Acadia, page-44

Acadia downgraded to Sell at Goldman Sachs. PT $12

https://m.thefly.com/search/ACAD

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) was downgraded by equities researchers at The Goldman Sachs Group from a “neutral” rating to a “sell” rating in a research note issued on Thursday, The Fly reports.

Several other equities analysts have also commented on the stock. Loop Capital assumed coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday. They issued a “hold” rating and a $17.00 price objective on the stock. SVB Leerink decreased their price objective on shares of ACADIA Pharmaceuticals from $27.00 to $21.00 and set an “outperform” rating on the stock in a report on Tuesday, August 9th. Cowen decreased their price objective on shares of ACADIA Pharmaceuticals from $32.00 to $21.00 and set an “outperform” rating on the stock in a report on Monday, August 8th. StockNews.com lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, Citigroup increased their target price on shares of ACADIA Pharmaceuticals from $15.00 to $17.00 in a report on Tuesday, August 9th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, ACADIA Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $22.32.